

PSORIATIC ARTHRITIS: A DISTINCT COMPLEX DISEASE

Psoriatic arthritis is a painful, chronic inflammatory disease characterized by pain, stiffness, swelling and tenderness of the joints, inflammation of specific ligaments and tendons, and decrease in physical functioning¹.

IT IS ESTIMATED THAT NEARLY

38 MILLION PEOPLE WORLDWIDE



HAVE **PSORIATIC ARTHRITIS**^{2,3}

Health Economics


Psoriatic arthritis places a high burden on workplace productivity and healthcare resources

APPROXIMATELY
\$8,367
to
\$18,110

Average annual direct and indirect cost per person⁴

\$1.9 BILLION


Direct annual healthcare cost in the United States⁵



Direct costs due to hospitalizations⁴



Disability and lost productivity account for the majority of indirect costs⁴



People with psoriatic arthritis are unemployed⁴

Diagnosis

AVERAGE TIME:
5 YEARS
AFTER SYMPTOM ONSET⁶

USUALLY DEVELOPS BETWEEN THE AGES OF

30
AND
50⁷

Symptoms



Stiffness, pain, swelling & tenderness in joints, ligaments & tendons



ENTHESITIS:
Inflammation of the sites where tendons and ligaments insert into the bone



DACTYLITIS:
Inflammation of the entire finger or toe¹

Comorbidities

Approximately **42%** have **3 or more**



CARDIOVASCULAR DISEASE



DIABETES



OBESITY



CROHN'S DISEASE
& other inflammatory bowel disorders



LUPUS⁸
& other autoimmune diseases

Impact on Quality of Life



LESS ACTIVE
THAN THEY
ONCE WERE



IMPACTS
ABILITY
TO WORK



DIFFICULTY
GETTING IN &
OUT OF CAR⁹

Unmet Medical Need

People with psoriatic arthritis:



said therapy was burdensome⁴



who began therapy with an oral DMARD* changed therapy within one year¹⁰



stated that they were not receiving any treatment or topical treatment only⁹

*disease-modifying anti-rheumatic drug

¹ Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-864.

² World Psoriasis Day Consortium. "Key Communication Messages." Key Communication Messages. Accessed 23 Dec. 2013. <http://www.worldpsoriasisday.com/web/page.aspx?refid=110>.

³ World Psoriasis Day Consortium. "Facts about Psoriasis." Facts about Psoriasis. Accessed 23 Dec. 2013. <http://www.worldpsoriasisday.com/web/page.aspx?refid=130>.

⁴ Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35(12):680-689.

⁵ Lee, Seina, et al. The Burden of Psoriatic Arthritis. Pharmacy and Therapeutics 35. 12 (2010): 680-89

⁶ Lebwohl M, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. Journal of the American Academy of Dermatology. 2014. [http://www.jaad.org/article/S0190-9622\(14\)00977-3/abstract](http://www.jaad.org/article/S0190-9622(14)00977-3/abstract)

⁷ National Psoriasis Foundation. (2013). Media kit. Retrieved from <http://www.psoarthritis.org/file/communications-all-documents/MediaKit.pdf>.

⁸ Husted JA, Thavaneswaran A, Chandran V, Gladman DD. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40(8):1349-56.

⁹ National Psoriasis Foundation. (2011). 2011 survey panel snapshot. Retrieved from <http://www.psoarthritis.org/document.doc?id=1782>.

¹⁰ Zhang F, Gauthier G, Hiscock R, Curtis J. Treatment patterns in psoriatic arthritis patients newly initiated on non-biologic disease-modifying anti-rheumatic drugs. Presented at the 12th Annual Meeting of the ACR/ARHP. November 10-14, 2012; Washington, DC.

To learn more about psoriatic arthritis, go to www.discoverpsa.com.

